Skip to main content
. 2018 May 29;9(41):26417–26430. doi: 10.18632/oncotarget.25443

Figure 6. Orthogonal validation between F1H and TARGET platforms.

Figure 6

(A) Among genes covered by both panels, 69/80 (86%) of results were concordant. Among the discordant results (n = 9), those identified by F1H only were explained (n = 7) by the targeted exome sequencing utilized by TARGET. Among the 2 samples not identified as somatic by F1H, these were whole exon deletions of CBL that were not called as likely somatic by the platform. (B) Correlation of VAF results for FLT3/ITD between the 2 platforms demonstrated a high degree of correlation, with the F1H platform able to detect somatic mutations at high sensitivity with regard for allele frequency.